SELENOP and metabolic dysfunction-associated steatotic liver disease: In conclusion, in this in vivo study performed in a well-characterized cohort of non-diabetic subjects with NAFLD, we observed an interplay between circulating SeP and metabolic derangements, providing a new piece in the complex puzzle of NASH progression and liver fibrogenesis.